Emcure Pharmaceuticals Limited acquired worldwide rights for BiCNU injection from Bristol-Myers Squibb Company (NYSE:BMY) in cash in December, 2012. Emcure Pharmaceuticals will fund the acquisition in a combination of debt and internal accruals. Emcure will buy all other marketing rights and authorizations held by Bristol-Myers Squibb on a global basis following a transition period during which Bristol-Myers Squibb will continue to distribute the product. After acquisition, Emcure plans to sell the product through its subsidiaries, including Heritage Pharmaceuticals, Inc. in the United States, and in some cases, through Emcure's marketing and distribution partners. Emcure will acquire the marketing rights and authorizations, trademarks, technology and the know-how related to the product following a transition period during which Bristol-Myers will continue to distribute the product.

Emcure Pharmaceuticals Limited agreed to acquire worldwide rights for BiCNU injection from Bristol-Myers Squibb Company (NYSE:BMY) in December, 2012.